Spun out of George Church's lab, this biotech upstart is mapping the AAV universe for Novartis, Sarepta to gaze
In a few days, through a series of video conferences, gene therapy researchers around the world will be presenting their latest findings at the virtual annual meeting of the American Society of Gene & Cell Therapy. Almost every discussion will feature a topic that has been central to the existence of the field but continues to perplex experts as they seek to refine the modality: the delivery of a gene to the tissue where it’s needed to fix disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
